TAS-120

DRUG4 trials

Conditions

Advanced CholangiocarcinomaAdvanced or Metastatic Solid TumorAlveolar Soft Part SarcomaBiliary Tract CancerColorectal CancerEsophageal CancerFGFR2 FusionsGastric Cancer

Phase 1

AB122 Platform Study

RecruitingNCT04999761

Taiho Pharmaceutical Co., Ltd.Advanced or Metastatic Solid Tumor, Alveolar Soft Part Sarcoma, Biliary Tract Cancer +6

Start: 2021-06-01End: 2026-05-31Target: 917Updated: 2024-09-25

Phase 2

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

RecruitingNCT05727176

Taiho Oncology, Inc.Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement

Start: 2023-07-05End: 2026-12-31Target: 120Updated: 2025-12-29

Phase 3

Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruitingNCT03784014

Institut National de la Santé Et de la Recherche Médicale, FranceSoft Tissue Sarcoma

Start: 2019-10-19End: 2026-01-13Updated: 2025-12-11

Unknown Phase

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

NCT04507503

Taiho Oncology, Inc.Advanced Cholangiocarcinoma

Updated: 2026-03-10

Related Papers

Zimberelimab platform study: Safety and efficacy of zimberelimab in combination with futibatinib and chemotherapy in patients with first-line advanced or metastatic esophageal carcinoma.

Journal of Clinical Oncology2025-01-27

FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (<i>FGFR2</i>) fusions/rearrangements.

Journal of Clinical Oncology2024-01-202 citations

Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.

2021-11-0512 citations

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Genome Medicine2021-05-1853 citations